Eli Lilly and Company (LLY)
US judge denies injunction to stop bar on copies of Lilly weight loss drug
A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S.
Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors
Whatever you think of Donald Trump's tariff policies, one fact stands out: companies are looking to invest more in the United States. They want to avoid the negative impacts of tariffs on their business.
Eli Lilly and Company (LLY) TD Cowen 45th Annual Health Care Conference (Transcript)
Eli Lilly and Company (NYSE:LLY ) TD Cowen 45th Annual Health Care Conference March 4, 2025 1:50 PM ET Company Participants Jake Van Naarden - President of Lilly Oncology Conference Call Participants Stephen Scala - TD Cowen Stephen Scala Good afternoon, and welcome once again to TD Cowan's 45 Annual Health Care Conference. We're delighted to have with us, again this year, Eli Lilly.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in Europe
The CHMP gives a positive opinion to Eli Lilly's Jaypirca in patients with relapsed or refractory CLL in a post-BTK inhibitor setting.
Where Will Eli Lilly Be in 5 Years?
It's hard to argue with the kinds of results Eli Lilly (LLY 1.71%) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares leaving the broader market in the dust.
Eli Lilly takes aim at weight-loss drug copies with new ad campaign
Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its latest attempt to fend off competition from copies of its weight-loss drug.
Eli Lilly investing $27B more in US manufacturing
Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.
Eli Lilly plans to invest $27B to build four new US plants as tariffs loom
Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 construction workers.
Eli Lilly Latest US Company to Commit to Domestic Investments
Eli Lilly (LLY) plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S., as the company looks to ramp up its domestic drug productions amid the threat of possible tariffs.
Eli Lilly announces $27B investment in US drug manufacturing
Eli Lilly and Co (NYSE:LLY) plans to invest at least $27 billion in four new US manufacturing facilities, the company announced during an event in Washington DC. Three of the facilities will focus on producing active pharmaceutical ingredients (APIs) for drugs like Zepbound and Mounjaro, while the fourth will expand the company's capacity for future injectable medications.
Eli Lilly to spend $27 billion to expand U.S. manufacturing with four new sites
Eli Lilly & Co.'s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.
